Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0DKNMD
ADC Name
MAb-DMBA-SIL-MMAE
Synonyms
MAb DMBA SIL MMAE
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Thyroid cancer [ICD11:2D10]
Investigative
Drug-to-Antibody Ratio
5.57
Structure
Antibody Name
Cetuximab
  Antibody Info 
Antigen Name
Epidermal growth factor receptor (EGFR)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
DMBA-SIL
  Linker Info 
Conjugate Type
Site-specific conjugation with the respective EGFR mAb via thiolmaleimide Michael addition.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.1
nM
8505C cells
Thyroid gland anaplastic carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.10 nM
Method Description
Cytotoxicity of non-irradiated or X-ray-irradiated (8 Gy) mAb-DMBA-SIL-MMAE conjugate in comparison to free MMAE in anaplastic thyroid cancer.
In Vitro Model Thyroid gland anaplastic carcinoma 8505C cells CVCL_1054
References
Ref 1 Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release. Bioconjug Chem. 2022 Aug 17;33(8):1474-1484.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.